Effect of Salbutamol, Beclometazone nasal spray Atrovent Inhaler on pulmonary complications after Coronary artery bypass grafting (CABG)

Comparison of three methods of preparing heavy smokers, quit smokers, non-quitters, under treatment with inhaler salbutamol_atrovent_ beclometazone with normal spirometry on respiratory complications after Coronary artery bypass grafting (CABG)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014052514359N2

Enrollment

225

Registered

2014-07-09

Start date

2014-08-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary complications in heavy smokers. ?????? ?????

Interventions

Intervention 1: Intervention 1) smokers haven’t been treated and smoked before surgery. Intervention 2: Intervention2: smokers have been treated with salbutamol_atrovent _ beclometazon and smoked bef

Prevention

Intervention 1) smokers haven’t been treated and smoked before surgery

Intervention2: smokers have been treated with salbutamol_atrovent _ beclometazon and smoked before surgery.

Intervention 3: Smokers have quit smoking for 8 weeks.

Eligibility

Sex/Gender

All

Age

35 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 65-35 years old;Heavy smokers;Normal spirometry Exclusion criteria: Fever; Cough; Sputum

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Cough. Timepoint: first and second days after surgery. Method of measurement: times per minute/question.;Wheezing. Timepoint: first and second days after surgery. Method of measurement: Hearing lung.;Rals. Timepoint: first and second days after surgery. Method of measurement: Hearing lung.;Time of mechanical ventilation. Timepoint: 8 hours after surgery. Method of measurement: curve report.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVali Imantalab

Guilan University of Medical Sciences

arcguilan1392@gmail.com; vimantalb@yahoo.com+98 13 1666 9066

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026